NCT01576185

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 10 (actual)
• Sponsor: Children's Oncology Group · Network
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

These laboratory trial studies the development and treatment of a mouse model for acute myeloid leukemia (AML) using samples from younger patients with AML. Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about cancer and how well patients will respond to treatment.

Detailed description

PRIMARY OBJECTIVES: I. To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD scid gamma (NSG) mice. II. To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase inhibitors. OUTLINE: Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.

Conditions

• Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

Interventions

Type	Name	Description
OTHER	laboratory biomarker analysis	Correlative studies
DRUG	quizartinib	Via gavage
DRUG	sorafenib tosylate	Via gavage

Timeline

• Start date: 2012-05-01
• Primary completion: 2016-05-01
• Completion: 2016-05-01
• First posted: 2012-04-12
• Last updated: 2016-05-17

Locations

1 site across 1 country: United States